Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-
Boehringer Ingelheim and OSE Immunotherapeutics enter into a global license ...
2018-04-10
文传商讯
Boehringer Ingelheim Marks Great Progress in Immuno-oncology Research P
New Industry and Academic Partnerhips Build on Company’s Succeses and Reinf...
2017-12-13
文传商讯
Faslodex (Fulvestrant) Receives EU Approval for the Treatment of Hormon
First EU approval for fulvestrant in combination with a CDK4/6 inhibitor Fu...
2017-11-17
文传商讯
FASLODEX (FULVESTRANT) RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT
Positive opinion is based on Phase III trial data demonstrating a 4.9 month ...
2017-10-17
文传商讯
Lynparza (olaparib) Maintenance Treatment Offers Sustained Quality of L
Change in functional assessment of ovarian cancer therapy (FACT-O TOI) simil...
2017-06-05
文传商讯
Boehringer Ingelheim expands collaboration with Vanderbilt University t
New collaboration with Vanderbilt University investigates novel approaches t...
2017-03-06
文传商讯
Boehringer Ingelheim HCP Survey: Nearly 20% of newly diagnosed lung can
International survey showed high global EGFR testing rates prior to first-li...
2016-12-09
文传商讯
Faslodex Demonstrates Progression-Free Survival Advantage in 1st Line A
Faslodex reduces risk of progression by 20% and extends median progression-f...
2016-10-11
文传商讯
Takeda Supports Global Expansion of the American Cancer Society’s Rela
Expansion will introduce RFL to 20 new countries over the next five years NE...
2016-09-13
文传商讯
Takeda Supports Global Expansion of the American Cancer Society’s Rela
Expansion will introduce RFL to 20 new countries over the next five years NE...
2016-09-13
文传商讯
